PMID- 37294963
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20230717
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Print)
IS  - 0278-0232 (Linking)
VI  - 41 Suppl 1
IP  - Suppl 1
DP  - 2023 Jun
TI  - CAR T-cell therapy in large B cell lymphoma.
PG  - 112-118
LID - 10.1002/hon.3153 [doi]
AB  - CD19-targeted chimeric antigen receptor (CAR) T-cells have revolutionized the 
      treatment of lymphoid malignancies, including large B cell lymphoma (LBCL). 
      Following seminal early phase multicenter clinical trials published between 2017 
      and 2020, three CD19-CAR T-cell products received FDA and EMA approval 
      designations in lymphoma in the third-line setting, paving the way for follow-up 
      studies in the second-line. Meanwhile, investigations into the applications of 
      CAR T-cell therapy have further broadened to treating high-risk patients even 
      prior to completion of first-line conventional chemo-immunotherapy. Furthermore, 
      as early trials excluded patients with central nervous system involvement with 
      lymphoma, several studies have recently shown promising efficacy of CD19-CAR 
      T-cells in primary and secondary CNS lymphoma. Here we provide a detailed 
      overview on clinical data supporting the use of CAR T-cells in patients 
      with LBCL.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Boardman, Alexander P
AU  - Boardman AP
AD  - Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, 
      USA.
FAU - Salles, Gilles
AU  - Salles G
AD  - Memorial Sloan Kettering Cancer Center, Lymphoma Service, New York, New York, 
      USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Receptors, Antigen, T-Cell)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - Receptors, Antigen, T-Cell/genetics/therapeutic use
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology
MH  - T-Lymphocytes
MH  - *Central Nervous System Neoplasms/drug therapy
MH  - Antigens, CD19
MH  - Multicenter Studies as Topic
PMC - PMC10348487
MID - NIHMS1898680
OTO - NOTNLM
OT  - B-cell lymphoma
OT  - CD19
OT  - autologous stem cell transplantation (ASCT)
OT  - chimeric antigen receptor (CAR) T cell
OT  - diffuse large B-cell lymphoma (DLBCL)
OT  - non-Hodgkin lymphoma (NHL)
OT  - primary CNS lymphoma (PCNSL)
OT  - secondary CNS lymphoma (SCNSL)
EDAT- 2023/06/09 19:42
MHDA- 2023/06/12 06:42
PMCR- 2024/06/01
CRDT- 2023/06/09 17:25
PHST- 2023/03/28 00:00 [received]
PHST- 2023/03/28 00:00 [accepted]
PHST- 2024/06/01 00:00 [pmc-release]
PHST- 2023/06/12 06:42 [medline]
PHST- 2023/06/09 19:42 [pubmed]
PHST- 2023/06/09 17:25 [entrez]
AID - 10.1002/hon.3153 [doi]
PST - ppublish
SO  - Hematol Oncol. 2023 Jun;41 Suppl 1(Suppl 1):112-118. doi: 10.1002/hon.3153.